340B covered entities are telling Congress that while they support federal action to lower drug prices, they worry that changes could weaken the 340B program and the wider health care safety net.

Providers Concerned About Drug Pricing Reform’s Potential to Undermine 340B

340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content